NVC-001 is designed to target the mechanobiological root cause of LMNA dilated cardiomyopathy and has disease-modifying potential SINGAPORE, PARIS and PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- Nuevocor, a clinical-stage biotechnology company pioneering mechanobiology-targeted therapies designed to address the root causes of life-threatening cardiomyopathies, today announced that the first...
HONG KONG, May 30, 2026 /PRNewswire/ -- As an emerging segment at the intersection of intelligent manufacturing and creative consumption, the global consumer 3D...
HONG KONG, May 30, 2026 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS) today announced that it received a notification letter (the...